Benefits of Vaccines for Kids 5-11 Far Outweigh Risks, UAB Doc Says
The benefits of the Pfizer vaccine for children ages 5 to 11, which is slated to go to the U.S. Food and Drug Administration for approval next week, far outweigh its risk to children, said Dr. David Kimberlin, co-director of UAB and Children's of Alabama's pediatrics division. He called his press conference Wednesday the most upbeat one in months, saying the delta variant of COVID-19 has receded. But the doctor warned that if another virus variant surfaces, the public should increase preventative measures. Kimberlin said vaccine data given Tuesday by an external advisory board to the FDA about the safety of vaccines for ages 5 to 11 is “incontrovertible.” Read more.